CSL vows to fight rival’s patent claim

VACCINES and blood products developer CSL says it will vigorously fight a patent infringement claim launched by US-based biotech Bioverativ in relation to CSL’s haemophilia B drug, Idelvion.

Bioverativ, which develops treatments for haemophilia and other rare blood disorders, has filed complaints in the US District Court with the International Trade Commission. It claims that Idelvion infringes three Bioverativ patents.

Read more